financetom
Business
financetom
/
Business
/
Align Technology Q2 Adjusted Earnings Rise, Revenue Falls; Plans Job Cuts; Shares Decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Align Technology Q2 Adjusted Earnings Rise, Revenue Falls; Plans Job Cuts; Shares Decline
Jul 30, 2025 3:13 PM

05:44 PM EDT, 07/30/2025 (MT Newswires) -- Align Technology ( ALGN ) reported Q2 adjusted earnings late Wednesday of $2.49 per diluted share, up from $2.41 a year earlier.

Analysts polled by FactSet expected $2.57.

Revenue for the quarter ended June 30 was $1.01 billion, down from $1.03 billion a year earlier.

Analysts surveyed by FactSet expected $1.06 billion.

The company said it expects Q3 revenue to be in the range of $965 million to $985 million. Analysts polled by FactSet expect $1.04 billion.

Align also plans to take a series of actions to streamline operations, including global workforce reduction. It expects these actions to result in one-time charges of $150 million to $170 million in H2.

Shares of Align Technology ( ALGN ) were down over 35% in after hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Artis Wraps Up Strategic Review and Says Will
Artis Wraps Up Strategic Review and Says Will "Continue to Pursue the REIT's Existing Business Strategy"
Dec 12, 2024
03:40 PM EST, 12/12/2024 (MT Newswires) -- Artis Real Estate Investment Trust (AX-UN.TO) Thursday announced that it has concluded a near 16-month strategic review process and in the end will continue to purse the REIT's existing business strategy while turning its attention to unspecified growth opportunities that it believes will produce above average risk-adjusted returns and grow net asset value...
ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray
ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray
Dec 12, 2024
03:36 PM EST, 12/12/2024 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said its licensing partners in China, Japan and Australia have submitted approval applications for its epinephrine nasal spray called neffy 2 mg. The phase 3 trial of the nasal spray in Japanese patients aged 6 to 17, who had anaphylactic symptoms after food, had a 100% success rate...
What's Going On With Nikola Stock Thursday?
What's Going On With Nikola Stock Thursday?
Dec 12, 2024
Nikola Corp ( NKLA ) shares are trading lower Thursday following a report indicating the company confirmed another round of layoffs. What Happened: Nikola ( NKLA ) has confirmed a fresh round of layoffs just months after the company slashed approximately 15% of its workforce as it attempts to avoid bankruptcy, according to Electrek. The report indicates that it’s not...
Update: Market Chatter: ExxonMobil, Lobbyist Under Scrutiny for Hacking Claim
Update: Market Chatter: ExxonMobil, Lobbyist Under Scrutiny for Hacking Claim
Dec 12, 2024
03:35 PM EST, 12/12/2024 (MT Newswires) -- (Updates with statement from ExxonMobil ( XOM ) in the third paragraph.) ExxonMobil ( XOM ) and one of its longtime lobbyists are facing calls for scrutiny and accountability following a scandal in which the email accounts of US critics of the energy giant were hacked, Reuters reported Thursday. US Senators Sheldon Whitehouse...
Copyright 2023-2026 - www.financetom.com All Rights Reserved